Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).
The review found no eligible studies for this question.
Antidepressants showed no clear difference in maintenance of remission at 12 months compared with placebo (low certainty).
It is very uncertain whether antidepressants changes endoscopic relapse at 12 months compared with placebo (very low certainty).
It is very uncertain whether elemental changes remission rate ‐ Intention to treat compared with non‐elemental enteral feeds (very low certainty).
It is very uncertain whether elemental changes adverse events compared with non‐elemental enteral feeds (very low certainty).
It is very uncertain whether elemental changes withdrawal due to adverse events compared with non‐elemental enteral feeds (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT adult studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT pediatric studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ per‐protocol ‐ pediatric studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes adverse events compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes withdrawal due to adverse events compared with corticosteroids (very low certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus taxane compared with gemcitabine alone (high certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus other agent(s) compared with gemcitabine alone (low certainty).
Fluoropyrimidine combinations showed no clear difference in overall survival compared with fluoropyrimidine alone (low certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).